TITLE

Patently necessary: improving global access to essential medicines

PUB. DATE
December 2003
SOURCE
CMAJ: Canadian Medical Association Journal;12/9/2003, Vol. 169 Issue 12, p1257
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Deals with issues concerning several legislative measures to address global health problems. Controversy associated with several trends and events in various countries; Details of the U.S. federal government's pledge to amend the Patent Act, which is aimed at addressing issues related to the export of generic versions of patented drugs; Provisions of Bill C-56 that addressed pharmaceutical services to various countries.
ACCESSION #
11528267

 

Related Articles

  • Report of the WHO Advisory Committee on Safety of Medicinal Products.  // WHO Technical Report Series;2005, Issue 933, p6 

    The article highlights the report of the World Health Organization Advisory Committee on Safety of Medicinal Products. It discusses the establishment of a high-level Advisory Committee on Safety of Medicinal Products. The Committee has expressed a strong interest in contributing to the work of...

  • Reprivatizing Pharmaceutical Supplies in Africa. Turshen, Meredeth // Journal of Public Health Policy;2001, Vol. 22 Issue 2, p198 

    Perhaps no part of the health system is as imperiled by neoliberal economic reforms as the public drug sector. The national bill for pharmaceuticals can claim one-third of a developing country's annual health budget. This article describes the essential drugs program created by WHO in the 1980s...

  • Counterfeit and substandard quality of drugs: The need for an effective and stringent regulatory control in India and other developing countries. Khan, Azhar Yaqoob; Ghilzai, Naushad M. Khan // Indian Journal of Pharmacology;Aug2007, Vol. 39 Issue 4, p206 

    The article discusses the implications of counterfeit and substandard quality of drugs on an effective and stringent regulatory control in India and other developing countries. The World Health Organization (WHO) defined counterfeit drug as one which is deliberately and fraudulently mislabeled...

  • WHO Prequalfication of Medicines Programme.  // WHO Drug Information;2010, Vol. 24 Issue 2, p87 

    The article discusses the World Health Organization's (WHO) prequalification of medicines program, which features inspections of pharmaceutical product manufacturers that are carried out in an effort to prevent the manufacturing and marketing of counterfeit drugs. A survey which the organization...

  • OPENING DOORS TO RESEARCH. Lanjouw, Jean Olsow // Brookings Review;Spring2003, Vol. 21 Issue 2, p13 

    Focuses on the dispute between the pharmaceutical industry and advocates for the poor over patent protection in developing countries. Proposal for a patent system that recognizes differences in the well-being of countries and encourages the private sector to get involved in creating drugs for...

  • Drug giants drop suit against South African drug law. Sibbald, Barbara // CMAJ: Canadian Medical Association Journal;5/29/2001, Vol. 164 Issue 11, p1608 

    Reports that international drug companies have withdrawn their challenge to a South African law that will allow the government to import or produce generic versions of patented drugs. How Africans suffering from HIV and AIDS cannot afford the patented drugs; Suggestion that other countries will...

  • How Do Patents And Economic Policies Affect Access To Essential Medicines In Developing Countries? Attaran, Amir // Health Affairs;May/Jun2004, Vol. 23 Issue 3, p155 

    This paper studies the relationship between patents and access to essential medicines. It finds that in sixty-five low- and middle-income countries, where four billion people live, patenting is rare for 319 products on the World Health Organization's Model List of Essential Medicines. Only...

  • Counterfeit drugs and medical devices in developing countries. Glass, Beverley D. // Research & Reports in Tropical Medicine;2014, Vol. 5, p11 

    The World Health Organization has reported that counterfeit medicines potentially make up more than 50% of the global drug market, with a significant proportion of these fake products being encountered in developing countries. This occurrence is attributed to a lack of effective regulation and a...

  • Combatting Substandard and Falsified Medicines: A View from Rwanda. Binagwaho, Agnes; Bate, Roger; Gasana, Michel; Karema, Corine; Mucyo, Yves; Mwesigye, John Patrick; Biziyaremye, Floribert; Nutt, Cameron T.; Wagner, Claire M.; Jensen, Paul; Attaran, Amir // PLoS Medicine;Jul2013, Vol. 10 Issue 7, p1 

    Agnes Binagwaho and colleagues describe Rwanda's experience of pharmacovigilance for malaria and tuberculosis, and call for a global treaty and leadership by the World Health Organization to address the global manufacture and trade in substandard and falsified medicines. Please see later in the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics